{"commentary":{"count":32,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":18,"podcast":11,"x_thread":3},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06103864\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT06103864","nct_id":"NCT06103864","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct06103864. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Arm 1: Dato-DXd + durvalumab","label":"Dato-DXd + durvalumab","type":"EXPERIMENTAL"},{"description":"Arm 2: Investigator's Choice of Chemotherapy (ICC) in combination with pembrolizumab (paclitaxel, nab-paclitaxel, or gemcitabine + carboplatin)","label":"Investigator's Choice of Chemotherapy (ICC) in combination with pembrolizumab","type":"ACTIVE_COMPARATOR"},{"description":"Arm 3: Dato-DXd","label":"Dato-DXd","type":"EXPERIMENTAL"}],"collaborators":["Daiichi Sankyo"],"completion_date":{"date":"2030-09-30","type":"ESTIMATED"},"conditions":["Breast Cancer"],"enrollment":{"count":625,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Dato-DXd","type":"DRUG"},{"name":"Durvalumab","type":"DRUG"},{"name":"Paclitaxel","type":"DRUG"},{"name":"Nab-paclitaxel","type":"DRUG"},{"name":"Gemcitabine","type":"DRUG"},{"name":"Carboplatin","type":"DRUG"},{"name":"Pembrolizumab","type":"DRUG"}],"last_update":"2026-09-25","lead_sponsor":"AstraZeneca","official_title":"A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2027-07-28","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression Free Survival (PFS)","timeFrame":"From randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause (anticipated to be up to 33 months)."}],"references":[{"citation":"Schmid P, Oliveira M, O'Shaughnessy J, Cristofanilli M, Graff SL, Im SA, Loi S, Saji S, Wang S, Cescon DW, Hovey T, Nawrot A, Tse K, Vukovic P, Curigliano G. TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer. Ther Adv Med Oncol. 2025 Apr 17;17:17588359251327992. doi: 10.1177/17588359251327992. eCollection 2025.","pmid":"40297626","type":"DERIVED"}],"start_date":{"date":"2023-11-23","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)","url":"https://clinicaltrials.gov/study/NCT06103864"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct06103864"}